Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.
Scientific Claim
Tesamorelin reduces visceral adipose tissue by approximately 18% in HIV-infected patients with central fat accumulation after 12 months of continuous treatment (P < 0.001).
Original Statement
“VAT was reduced by approximately 18% (P < 0.001) in patients continuing tesamorelin for 12 months.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study is a randomized controlled trial with a control group, which allows for causal inference. The verb 'reduces' is appropriate for this design.
Evidence from Studies
Supporting (1)
Unknown Title
This study found that a drug called tesamorelin helped HIV patients lose about 18% of their dangerous belly fat after a year of daily shots, and the results were strong and reliable.